Funding for this research was provided by:
Received: 18 June 2021
Accepted: 29 June 2022
First Online: 15 July 2022
: A.B. has provided consulting or advisory roles for Astra Zeneca/Daiichi Sankyo, Lilly, Foundation Medicine, Gilead, Novartis, Genentech, Pfizer, Spectrum Pharmaceuticals, bioTheranostics, Merck, Radius Health, Immunomedics, Sanofi, and Puma Biotechnology, an institution consulting or advisory role for Immunomedics, Novartis, Genentech/Roche, Pfizer, Radius Health, Sanofi, and Innocrin Pharmaceuticals, and has received research funding from bioTheranostics. S.C. has received research support (to Memorial Sloan Kettering) from Daiichi Sankyo and Paige.ai, clinical trial funding (to Memorial Sloan Kettering) from Sanofi, Novartis, and Lilly, and consulting honoraria (to S.C.) from AstraZeneca, Inivata, Lilly, Novartis Sanofi, and Targeted Oncology. H.M.L. has provided consulting or advisory roles for Eisai and Pfizer, and her institution has received funding from Zionexa, Sanofi, Zentalis, Eisai, and Zymeworks. G.A.U. has provided consulting and/or has received research support from GE Healthcare, Genentech, Sanofi, Novartis, Puma Biotechnology, Siemens, Zionexa, and Lantheus. A.G., S.C-C., P.C., S.D., G.P., M. Celanovic, V.P., J.E.M., N.T., M.B., J.S.L., and A-L.B. are employees of Sanofi and may hold shares and/or stock options in the company. M. Campone has provided consulting, advisory, or speaker roles for AbbVie, Accord Healthcare, AstraZeneca, Daiichi Sankyo, G1 Therapeutics, Lilly, Novartis, Pfizer, Pierre Fabre Oncology, Sandoz, Sanofi, Seagene, and Servier; and has received honoraria for travel from AstraZeneca, Novartis, Pfizer, and Roche.